Protocol Summary

Protocol No.: OCR24302

Sponsor Protocol No.: 20170543; 20170543;AMG510

Protocol Title.: A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreak 100)

Principal Investigator: George, Thomas

Objective: Evaluate the safety and tolerability of AMG 510 in adult subjects with KRAS p.G12C mutant advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with KRAS p.G12C mutant advanced solid tumors.

Phase: Phase I/II

Age Group: Adult

Age: 18 Years - 100 Years

Gender: All

Scope: National

Treatment:

Experimental: Dose Exploration Part 1 monotherapy
Cohorts with food effect and alternative dosing regimens Enrollment into the dose exploration cohorts may be from any eligible solid tumor type. Dose escalation will begin with 2-4 subjects treated at the lowest planned dose level of 180 mg. If no DLT is observed, dose escalation will continue to the next planned dose cohort

Experimental: Dose Expansion Part 2 monotherapy
Upon completing the dose exploration part of the study, dose expansion may proceed with 2 groups consisting of subjects with KRAS p.G12C mutant advanced solid tumors Dose expansion in these 2 groups may be done concurrently

Experimental: Phase 2 monotherapy
Additional subjects will be enrolled in the dose expansion to confirm the recommended phase 2 dose. Enrollment into phase 2 will be opened after confirmation of the recommended phase 2 dose

Experimental: Combination arm with AMG 510 and anti PD-1/L1
Additional subjects will be enrolled into the combination arm with AMG 510 in combination with an anti (PD-1/L1)

Experimental: Monotherapy treatment naive advanced NSCLC
Separate cohort of part 1 dose expansion patients to evaluate the safety and clinical activity of AMG 510 administered orally once daily in patients with previously untreated advanced NSCLC

Detailed Eligibility:

Inclusion Criteria:
- Men or women greater than or equal to 18 years old.
- Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12Cmutation identified through DNA sequencing.
Exclusion Criteria
- Active brain metastases from non-brain tumors.
- Myocardial infarction within 6 months of study day 1.
- Gastrointestinal (GI) tract disease causing the inability to take oral medication.

Applicable Conditions:

  • Anus
  • Bones and Joints
  • Brain and Nervous System
  • Breast
  • Cervix
  • Colon
  • Corpus Uteri
  • Esophagus
  • Eye and Orbit
  • Ill-Defined Sites
  • Kidney
  • Larynx
  • Lip, Oral Cavity and Pharynx
  • Liver
  • Lung
  • Melanoma, Skin
  • Other Digestive Organ
  • Other Endocrine System
  • Other Male Genital
  • Other Respiratory and Intrathoracic Organs
  • Other Skin
  • Other Urinary
  • Ovary
  • Pancreas
  • Prostate
  • Rectum
  • Small Intestine
  • Soft Tissue
  • Stomach
  • Thyroid
  • Unknown Sites
  • Urinary Bladder
  • Participation Institution:

  • No UF Health MRN : Steven Fischer
  • UF Gainesville : Steven Fischer
  • Contact:
    Steven Fischer
    Email: stfischer07@ufl.edu

    More Information: View study listing on ClinicialTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT03600883